Myriad Genetics at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Myriad Genetics at ASHG 2026 in Montréal: 2 presentations (2 posters).

Organization	ASHG 2026 Attendance
Myriad Genetics Salt Lake City, Utah	1 Lab Director · 1 other presenter
myriad.com\|LinkedIn Public company~2,700 people Myriad sells molecular diagnostic tests for hereditary cancer, oncology, and prenatal care. It serves patients, healthcare providers, and biopharma partners. Myriad fully launched FirstGene, its Multiple Prenatal Screen, a new commercial test now broadly available. › Myriad fully launched FirstGene, its Multiple Prenatal Screen, a new commercial test now broadly available. 2026-07 · source Myriad expanded Precise MRD availability to breast, colorectal, and renal cancer patients undergoing treatment and surveillance. 2026-06 · source Myriad named Raj Jampa chief technology officer effective June 1, 2026, a new technical leadership contact. 2026-06 · source Source: company newsroom Q2 2026 revenue $190.7M, down 11% › FY2026 guidance is $770M-$790M revenue with 66%-67% adjusted gross margin, signaling a cautious outlook. · 2026-07-30 ““Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year”; “Revenue \| $770 - $790”; “Adjusted Gross Margin % \| 66% - 67%.”” Source: results release	Poster Thu Oct 22 4:15 pm Part of Cancer Poster Thursday Session Localization of Large Rearrangements in PMS2 and PMS2CL using PacBio Exhibit & Poster Hall · Board 1004T Cancer syndromesDiagnosticsGenetic testingLong-read sequencing Poster Fri Oct 23 2:30 pm Part of Cancer Poster Friday Session Novel processed pseudogenes identified in a hereditary pan-cancer NGS panel Exhibit & Poster Hall · Board 1046F Cancer syndromesDiagnosticsGenetic testingLong-read sequencing

Organization

ASHG 2026 Attendance

Myriad Genetics

Salt Lake City, Utah

1 Lab Director · 1 other presenter

myriad.com|LinkedIn

Public company~2,700 people

Myriad sells molecular diagnostic tests for hereditary cancer, oncology, and prenatal care. It serves patients, healthcare providers, and biopharma partners.

Myriad fully launched FirstGene, its Multiple Prenatal Screen, a new commercial test now broadly available.

›

Myriad fully launched FirstGene, its Multiple Prenatal Screen, a new commercial test now broadly available.

2026-07 · source

Myriad expanded Precise MRD availability to breast, colorectal, and renal cancer patients undergoing treatment and surveillance.

2026-06 · source

Myriad named Raj Jampa chief technology officer effective June 1, 2026, a new technical leadership contact.

2026-06 · source

Source: company newsroom

Q2 2026 revenue $190.7M, down 11%

›

FY2026 guidance is $770M-$790M revenue with 66%-67% adjusted gross margin, signaling a cautious outlook. · 2026-07-30

““Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year”; “Revenue | $770 - $790”; “Adjusted Gross Margin % | 66% - 67%.””

Source: results release

Poster

Thu Oct 22
4:15 pm

Part of Cancer Poster Thursday Session

Localization of Large Rearrangements in PMS2 and PMS2CL using PacBio

Exhibit & Poster Hall · Board 1004T

Cancer syndromesDiagnosticsGenetic testingLong-read sequencing

Poster

Fri Oct 23
2:30 pm

Part of Cancer Poster Friday Session

Novel processed pseudogenes identified in a hereditary pan-cancer NGS panel

Exhibit & Poster Hall · Board 1046F

Cancer syndromesDiagnosticsGenetic testingLong-read sequencing

Instantly find 20 buyers from Myriad Genetics

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction